Advertisement

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Published:December 23, 2018DOI:https://doi.org/10.1016/j.ygyno.2018.12.008

      Highlights

      • Cabozantinib is a targeted kinase inhibitor with anti-ovarian cancer activity.
      • Cabozantinib compared to weekly paclitaxel had similar PFS but had worse OS and ORR.
      • Cabozantinib had worse gastrointestinal toxicities compared to paclitaxel.

      Abstract

      Introduction

      Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer.

      Methods

      This was an open label, 1:1 randomized study of cabozantinib 60 mg orally (PO) daily versus weekly paclitaxel 80 mg/m2 given 3 out of 4 weeks (NCT01716715); 111 patients were enrolled. Eligibility included persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and at least one but no >3 prior chemotherapy regimens.

      Results

      Median PFS was similar for both treatment groups and was 5.3 months for cabozantinib and 5.5 months for weekly paclitaxel (HR 1.11 (90% CI 0.77–1.61, p = 0.64)). Secondary analyses of overall survival (OS) and event free survival (EFS) showed that cabozantinib did not perform as well as weekly paclitaxel. Median OS for cabozantinib was 19.4 months and was not reached for weekly paclitaxel (HR 2.27 (90% CI 1.17–4.41, p = 0.04). EFS was also worse in the cabozantinib arm, 3.5 months, compared to weekly paclitaxel at 5.0 months (HR 1.81 (90% CI 1.24–2.63, p = 0.01). Overall response rate (ORR) was less for cabozantinib compared to weekly paclitaxel (7% versus 24.1%). Gastrointestinal toxicities, specifically nausea, diarrhea, and abdominal pain were worse in the cabozantinib arm.

      Conclusions

      Median PFS was similar for cabozantinib and weekly paclitaxel. However, OS, EFS, and ORR were worse for cabozantinib compared to weekly paclitaxel. Cabozantinib given at this dose and schedule cannot be recommended as a treatment for recurrent ovarian cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegal R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J. Clin. 2018; 68: 7-30
        • McGuire W.P.
        • Hoskins W.J.
        • Brady M.F.
        • Kucera P.R.
        • Partridge E.E.
        • Look K.Y.
        • et al.
        Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
        N. Engl. J. Med. 1996; 334: 1-6
        • Bookman M.A.
        • Brady M.F.
        • McGuire W.P.
        • Harper P.G.
        • Alberts D.S.
        • Friedlander M.
        • et al.
        Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
        J. Clin. Oncol. 2009 Mar 20; 27: 1419-1425
        • Aghajanian C.
        • Blank S.V.
        • Goff B.A.
        • Judson P.L.
        • Teneriello M.G.
        • Husain A.
        • et al.
        OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
        J. Clin. Oncol. 2012 Jun 10; 30: 2039-2045
        • Coleman R.L.
        • Brady M.F.
        • Herzog T.J.
        • Sabbatini P.
        • Armstrong D.K.
        • Walker J.L.
        • et al.
        Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2017; 18: 779-791
        • Pujade-Lauraine E.
        • Hilpert F.
        • Weber B.
        • Reuss A.
        • Poveda A.
        • Kristensen G.
        • et al.
        Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.
        J. Clin. Oncol. 2014 May 1; 32: 1302-1308
        • Yakes F.M.
        • Chen J.
        • Tan J.
        • Yamagucchi K.
        • Shi Y.
        • Yu P.
        • et al.
        Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
        Mol. Cancer Ther. 2011; 10: 2298-2308
        • Gherardi E.
        • Birchmeier W.
        • Birchmeier C.
        • Vande Woude G.
        Targeting MET in cancer: rationale and progress.
        Nat. Rev. Cancer. 2012; 12: 89-103
        • Zillhardt M.
        • Christensen J.G.
        • Lengyel E.
        An orally available small molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.
        Neoplasia. 2010; 12: 1-10
        • Vergote I.B.
        • Smith D.C.
        • Berger R.
        • Kurzrock R.
        • Vogelzang M.H.
        • Sella A.
        • et al.
        A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
        Eur. J. Cancer. 2017; 83: 229-236
        • Schoffski P.
        • Gordon M.
        • Smith D.C.
        • Kurzrock R.
        • Daud A.
        • Vogelzang M.J.
        • et al.
        Phase II randomized discontinuation trial of cabozantinib in patients with solid tumors.
        Eur. J. Cancer. 2017; 86: 296-304
        • Choueiri T.K.
        • Escudier B.
        • Powles T.
        • Tannir N.M.
        • Mainwaring P.N.
        • Rini B.I.
        • et al.
        Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomized, open label phase 3 trial.
        Lancet Oncol. 2016; 17: 917-927
        • Choueiri T.K.
        • Halabi S.
        • Sanford B.L.
        • Hahn O.
        • Michaelson M.D.
        • Walsh M.K.
        • et al.
        Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial.
        J. Clin. Oncol. 2017; 35: 591-597
        • Bersanelli M.
        • Buti S.
        Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.
        Ther. Adv. Med. Oncol. 2017; 9: 627-636
        • Elisei R.
        • Schlumberger M.J.
        • Muller S.P.
        • Schoffski P.
        • Brose M.S.
        • Shah M.H.
        • et al.
        Cabozantinib in progressive medullary thyroid cancer.
        J. Clin. Oncol. 2013; 31: 3639-3646
        • Schoffski P.
        • Gordon M.
        • Smith D.C.
        • Kurzrock R.
        • Daud A.
        • Vogelzang N.J.
        • et al.
        Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumors.
        Eur. J. Cancer. 2017; 86: 296-304
        • Freidlin B.
        • Korn E.L.
        • George S.L.
        • Gray R.
        Randomized clinical trial design for assessing noninferiority when superiority is expected.
        J. Clin. Oncol. 2007; 25: 5019-5023
        • Cannistra S.A.
        • Matulonis U.A.
        • Penson R.T.
        • Hambleton J.
        • Dupont J.
        • Mackey H.
        • et al.
        Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
        J. Clin. Oncol. 2007; 25: 5180-5186
        • Burger R.A.
        • Sill M.W.
        • Monk B.J.
        • Greer B.E.
        • Sorosky J.I.
        • et al.
        Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2007; 25: 5165-5171
        • Matulonis U.A.
        • Berlin S.
        • Ivy P.
        • Tyburski K.
        • Krasner C.
        • Zarwan C.
        • et al.
        Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
        J. Clin. Oncol. 2009; 27: 5601-5606
        • Friedlander M.
        • Hancock K.C.
        • Rischin D.
        • Messing M.J.
        • Stringer C.A.
        • Matthys G.M.
        • et al.
        A phase II open labeled, study evaluating pazopanib in patients with recurrent ovarian cancer.
        Gynecol. Oncol. 2010; 119: 32-37
        • Matulonis U.A.
        • Lee J.
        • Lasonde B.
        • Tew W.P.
        • Yehwalashet A.
        • Matei D.
        • et al.
        ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
        Eur. J. Cancer. 2013; 49: 121-131
        • Campos S.M.
        • Penson R.T.
        • Matulonis U.
        • Horowitz N.S.
        • Whalen C.
        • Pereira L.
        • et al.
        A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube, and peritoneal cancer.
        Gynecol. Oncol. 2013; 128: 215-220
        • Pignata S.
        • Lorusso D.
        • Scambia G.
        • Sambataro D.
        • Tamberi S.
        • Cinieri S.
        • et al.
        Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum resistant-refractory advanced ovarian cancer (MITO 11): a randomized, open-label, phase 2 trial.
        Lancet Oncol. 2015; 16: 561-568
        • Richardson D.L.
        • Sill M.W.
        • Coleman R.L.
        • Sood A.K.
        • Pearl M.L.
        • Kehoe S.M.
        • et al.
        Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer.
        JAMA Oncol. 2018; 4: 196-202
        • Markman M.
        • Blessing J.
        • Rubin S.C.
        • Connor J.
        • Hanjani P.
        • Waggoner S.
        Phase II weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2006; 101: 436-440
        • Ghamande S.
        • Lele S.
        • Marchetti D.
        • Baker T.
        • Odunsi K.
        Weekly paclitaxel in patients with recurrent or persistent ovarian cancer.
        Int. J. Gynecol. Cancer. 2003; 13: 142-147
        • Kita T.
        • Kikuchi Y.
        • Takano M.
        • Suzuki M.
        • Oowada M.
        • Konno R.
        • et al.
        The effect of single agent weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.
        Gynecol. Oncol. 2004; 92: 813-818
        • Konstantinopoulos P.
        • Brady W.E.
        • Farley J.
        • Armstrong A.
        • Uyar D.S.
        • Gershenson D.M.
        Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
        Gynecol. Oncol. 2018 Jul; 150: 9-13